This proposition is further supported by reports of impaired in vivo protection against CMV in HSCT patients with GvHD under intense immunosuppressive therapy, despite the detection of high levels of CMV-specific CD8+ T cells or of in vitro IFN-γ CD8+ response to CMV-specific peptides [40,41]. The gene discussed is CD8A; the disease is graft versus host disease.